UK:
Vaccine Research Relief
To print this article, all you need is to be registered or login on Mondaq.com.
The measure
Vaccine research relief (VRR) for SMEs will be reduced from 40%
to 20% from 1 April 2011 and will no longer be available to them
from 1 April 2012.
Who will be affected?
This will affect SMEs who currently claim VRR on qualifying
costs relating to research and development of certain vaccines or
medicines. Relief will continue to be available for large
companies.
When?
VRR will be reduced to 20% from 1 April 2011. SMEs will not be
able to claim VRR from 1 April 2012.
Our view
A very limited number of SMEs actually claim VRR. As a result,
the removal of the relief for SMEs should not significantly affect
business.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Tax from UK
Employee Tax | Recent Developments
Osborne Clarke
HMRC announced in the February 2024 issue of the Employer Bulletin that it is aligning its approach to providing advance assurance on certain termination payment enquiries.
Tax Relief On Debt For Companies
Lubbock Fine
When financing your business operations through borrowing, one of the main considerations will be whether the interest cost is deductible, and to what extent if it is. In the UK...
Foreign Capital Loss Election For Non-Doms
Lubbock Fine
The complex rules for capital gains tax relief for non-domiciled individuals (non-doms) aren't new, although significant proposed changes have been announced to the non-dom regime in the March 2024 Budget...